Effect of FAK inhibitor VS‐6063 (defactinib) on docetaxel efficacy in prostate cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0045|78|4|308-317

ISSN： 0270-4137

Source： THE PROSTATE, Vol.78, Iss.4, 2018-03, pp. : 308-317

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Characterization of Prognostic Factors and Efficacy in a Phase-II Study with Docetaxel and Estramustine for Advanced Hormone Refractory Prostate Cancer

By  

Oncology Research and Treatment, Vol. 28, Iss. 11, 2005-10 ,pp. : 573-578

Karger

Access to resources Recommend Favorite

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer

By  

CANCER, Vol. 119, Iss. 20, 2013-10 ,pp. : 3636-3643

John Wiley & Sons Inc

Access to resources Recommend Favorite

An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer

By  

Oncology Research and Treatment, Vol. 30, Iss. 7, 2007-06 ,pp. : 355-360

Karger

Access to resources Recommend Favorite

A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer

By  

Oncology, Vol. 66, Iss. 4, 2004-06 ,pp. : 281-287

Karger

Access to resources Recommend Favorite

Castrate-Resistant Prostate Cancer with Peritoneal Metastases Treated with Docetaxel-Based Chemotherapy

By  

Urologia Internationalis, Vol. 93, Iss. 1, 2013-11 ,pp. : 49-54

Karger

Access to resources Recommend Favorite